Skip to main content

Advertisement

SpringerLink
Log in

Treatment of CGD-associated Colitis with the IL-23 Blocker Ustekinumab

  • Letter to Editor
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Campbell EL, Bruyninckx WJ, Kelly CJ, Glover LE, McNamee EN, Bowers BE, et al. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. Immunity. 2014;40(1):66–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Horvath R, Rozkova D, Lastovicka J, Polouckova A, Sedlacek P, Sediva A, et al. Expansion of T helper type 17 lymphocytes in patients with chronic granulomatous disease. Clinical and experimental immunology. 2011;166(1):26–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, Anaya-O’Brien S, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114(2):462–8.

    Article  PubMed  Google Scholar 

  4. Sandborn WJ, Gasink C, Gao L-L, Blank M, Johanns J, Guzzo C, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 22 From the Certifi Trial. Gastroenterology.140(5):S-109

  5. Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin Mol Allergy. 2011;9(1):10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rodrigues-Sousa T, Ladeirinha AF, Santiago AR, Carvalheiro H, Raposo B, Alarcao A, et al. Deficient production of reactive oxygen species leads to severe chronic DSS-induced colitis in Ncf1/p47phox-mutant mice. Plos One. 2014;9(5):e97532.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kuijpers T, Lutter R. Inflammation and repeated infections in CGD: two sides of a coin. Cellular and molecular life sciences : CMLS. 2012;69(1):7–15.

    Article  CAS  PubMed  Google Scholar 

  8. Rieber N, Hector A, Kuijpers T, Roos D, Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. Clinical & developmental immunology. 2012;2012:252460.

    Article  Google Scholar 

  9. Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis. 2010;51(12):1429–34.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. The New England journal of medicine. 2012;367(16):1519–28.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Stanford University, 300 Pasteur Drive, Grant Building Room H307A, Stanford, CA, 94305, USA

    Manish J. Butte & David B. Lewis

  2. Division of Gastroenterology, Department of Pediatrics, Stanford University, Stanford, CA, USA

    K. T. Park

Authors
  1. Manish J. Butte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. T. Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David B. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manish J. Butte.

Additional information

Encapsulated summary: Ustekinumab dramatically improved severe colitis in CGD, but may increase risk of infections.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Butte, M.J., Park, K.T. & Lewis, D.B. Treatment of CGD-associated Colitis with the IL-23 Blocker Ustekinumab. J Clin Immunol 36, 619–620 (2016). https://doi.org/10.1007/s10875-016-0318-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-016-0318-x

Keywords

Search

Navigation